ZURICH - VERAXA Biotech files SEC registration for $1.3 billion SPAC merger

Published 17/07/2025, 14:04
ZURICH - VERAXA Biotech files SEC registration for $1.3 billion SPAC merger

ZURICH - VERAXA Biotech AG, a developer of antibody-based cancer therapies, announced Thursday it has filed a registration statement on Form F-4 with the U.S. Securities and Exchange Commission regarding its proposed business combination with Voyager Acquisition Corp. (NASDAQ:VACH). According to InvestingPro data, Voyager currently trades near its 52-week low of $9.95, with a market capitalization of $329.22 million.

The filing marks a significant step toward VERAXA becoming a publicly traded company on the NASDAQ exchange. According to the registration statement, VERAXA’s equity value contribution to the business combination will be approximately $1.3 billion. InvestingPro analysis indicates Voyager maintains strong liquidity with a current ratio of 5.81, suggesting robust financial positioning for the merger. Get access to 6 more exclusive ProTips and comprehensive financial metrics with InvestingPro.

Under the terms of the agreement announced on April 23, VERAXA shareholders will receive approximately 130 million ordinary shares of the combined company in exchange for their existing shares. Existing VERAXA shareholders and management will roll over 100% of their equity into the combined entity.

Assuming a share price of $10.00 and no redemptions by Voyager’s public shareholders, the combined company is expected to have an implied pro forma equity value of approximately $1.64 billion at closing.

"The filing of our Registration Statement marks a significant step forward in our path to accessing the public capital markets," said Christoph Antz, CEO and Co-Founder of VERAXA, in a press release statement.

Upon closing, VERAXA anticipates access to approximately up to $253 million in cash held in trust by Voyager, prior to transaction costs and assuming no redemptions by Voyager’s public shareholders.

The boards of directors of both companies have unanimously approved the business combination, which is expected to close in the fourth quarter of 2025, subject to shareholder approvals and other customary closing conditions.

VERAXA, founded on scientific breakthroughs from the European Molecular Biology Laboratory, focuses on developing antibody-based therapeutics including bispecific ADCs and T cell engagers. Based on InvestingPro’s Fair Value analysis, Voyager currently appears slightly overvalued, trading at a P/E ratio of 34.94. Discover more detailed valuation metrics and expert insights with an InvestingPro subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.